TGTX: New Data on BRIUMVI at AAN 2026 Could Surge Stock!

Introduction

TG Therapeutics (NASDAQ: TGTX) is a commercial-stage biotech focused on B-cell mediated diseases, most notably multiple sclerosis (MS) (breakthroughinvestors.com). Its flagship (and so far, sole marketed) product BRIUMVI (ublituximab-xiiy) is an anti-CD20 monoclonal antibody approved for relapsing forms of MS (breakthroughinvestors.com). Briumvi launched in the U.S. in January 2023 after FDA approval in late 2022 (breakthroughinvestors.com), and in early 2024 it became available in Europe via partner Neuraxpharm (breakthroughinvestors.com). Uptake has been strong – U.S. product revenue jumped from $92.0 million in 2023 to $313.7 million in 2024 (breakthroughinvestors.com), and then nearly doubled to $594.1 million in 2025 (ir.tgtherapeutics.com) as more MS patients started Briumvi. This report examines TGTX’s financial profile and valuation, and how new Briumvi data being presented at the American Academy of Neurology (AAN) 2026 meeting may act as a catalyst for the stock.

Dividend Policy & Yield

TGTX does not pay a dividend. In fact, the company has never declared or paid any cash dividends on its common stock (www.sec.gov). As an emerging biotech, TG Therapeutics has instead reinvested in product launches and R&D. Current debt covenants also restrict the payment of cash dividends, a restriction the company expects to continue (www.sec.gov). Given this policy, TGTX’s dividend yield is 0%, and investors’ returns are expected to come entirely from stock price appreciation. (Metrics like FFO/AFFO are not applicable here, as those are used for real estate companies; TGTX’s performance is measured by earnings and cash flow rather than funds from operations.)

Leverage, Debt Maturities & Coverage

TG Therapeutics carries a moderate amount of debt after financing its Briumvi launch. In August 2024, the company entered into a $250 million term loan facility with Blue Owl Capital and Healthcare Royalty (www.sec.gov) (www.sec.gov). This loan matures in August 2029 and accrues interest at a floating rate (a base rate plus a margin starting at 5.5% depending on sales performance) (www.sec.gov). The facility also includes an uncommitted additional $100 million tranche that TGTX can tap if needed (www.sec.gov). The term loan is secured by substantially all of TG’s assets and includes covenants (such as restrictions on dividends as noted) (www.sec.gov) (www.sec.gov).

As of year-end 2025, TGTX had total cash, equivalents and investments of about $199.5 million (intellectia.ai), providing liquidity for operations. Net debt was therefore modest (~$50 million net of cash/investments) relative to the company’s growing revenue base. In 2025, operating income was $123.3 million, while interest expense was $26.7 million (ir.tgtherapeutics.com) – an interest coverage of roughly 4.6×, indicating that operating profits comfortably covered interest obligations. With Briumvi sales ramping up, TG achieved profitability in 2025 (the first annual profit in its history) (koalagains.com) (koalagains.com), improving its ability to service debt. The company believes its existing cash plus projected revenues are sufficient to fund operations for at least 12 months beyond the 10-K filing date (www.sec.gov) (www.sec.gov). However, it’s worth monitoring cash flows: despite positive earnings, cash decreased by about $100 million in 2025 (www.sec.gov) (www.sec.gov), reflecting working capital needs and ongoing R&D investments. Management even raised additional equity capital (~$75 million in late 2025) to extend its cash runway through 2028 (intellectia.ai), underscoring a prudent approach to liquidity. Overall, TGTX’s leverage is manageable, with no major maturities until 2029 and interest-only payments until 2028, by which time Briumvi’s cash generation should be stronger (www.sec.gov) (www.sec.gov).

Valuation & Comparable Metrics

At around $27–30 per share in early 2026, TG Therapeutics’ market capitalization is roughly $4.0–4.5 billion. Considering the ~$250M debt and ~$200M cash/investments, the enterprise value (EV) is about $4.1–4.3 billion. This values the company at approximately 6.7× EV/sales on a trailing (2025) basis (with $616M total 2025 revenue (ir.tgtherapeutics.com) (ir.tgtherapeutics.com)) and about 4.5–5× EV/sales on a forward 2026 basis using the company’s revenue guidance of $875–900 million (ir.tgtherapeutics.com). Such multiples are not unusual for a high-growth biotech: analysts project a ~46% revenue CAGR from 2024 to 2028 as Briumvi scales globally (koalagains.com).

Traditional earnings-based metrics are in flux due to one-time accounting effects. TG reported GAAP net income of $447 million in 2025 (ir.tgtherapeutics.com), but this was boosted by a large non-cash tax benefit (release of valuation allowances on prior losses) (ir.tgtherapeutics.com). Excluding that, underlying earnings were much lower. Looking ahead, consensus expects earnings to normalize as tax benefits taper. Forward P/E for 2026 is estimated around 17× at current prices (www.gurufocus.com), reflecting optimism that TG can sustain profitability. A forward multiple in the high-teens is reasonable – if TGTX executes well, its growth rate could justify a higher valuation, but any stumble could make even 17× look expensive. It’s notable that GuruFocus’s quantitative model actually pegs TG’s intrinsic value at ~$60/share (with caveats of a “possible value trap”) (www.gurufocus.com), highlighting the uncertainty in valuing a single-product growth story. For another reference, TGTX’s price-to-sales ratio was around 8× in mid-2024, and has since compressed to mid-single-digits as sales have ramped (www.macrotrends.net). In summary, TGTX trades at a premium to established pharma (as expected for a growth biotech), but relative to its 40–50% annual growth and improving margins, the valuation appears reasonable – if Briumvi’s rollout stays on track.

New BRIUMVI Data at AAN 2026 – A Catalyst?

Investor focus is now on upcoming BRIUMVI data at the 2026 AAN Annual Meeting (April 18–22, 2026 in Chicago) (www.globenewswire.com). TG Therapeutics has announced several presentations highlighting Briumvi’s performance in MS patients (www.globenewswire.com). Notably, the company will present real-world data from ENABLE, the first Phase 4 observational study of Briumvi in relapsing MS (www.globenewswire.com). This real-world study should provide insight into Briumvi’s effectiveness and safety in routine clinical practice outside of controlled trials – important for physician confidence and payer adoption. Another presentation covers the ENHANCE trial updates, showing the safety and tolerability of a modified ublituximab dosing regimen (www.globenewswire.com). ENHANCE is evaluating a consolidated dosing schedule (combining the typical Day 1 and Day 15 infusions) to simplify treatment (www.sec.gov) (www.sec.gov). If the data show that a one-day or shortened initial dosing is feasible and safe, Briumvi could become more convenient relative to its main IV competitor Ocrevus (which requires a split first dose).

These AAN presentations follow strong data shown in 2025. At AAN 2025, TGTX showcased 5-year follow-up results from the Phase 3 ULTIMATE I & II trials, which demonstrated durable efficacy and safety of Briumvi (breakthroughinvestors.com). They also shared encouraging real-world infusion tolerability data and other analyses (breakthroughinvestors.com). The market reacted positively to those long-term results, as they underscored Briumvi’s competitive profile. Now, the 2026 AAN data could further boost confidence in Briumvi’s differentiators. Real-world evidence from ENABLE might show high efficacy or lower relapse rates in practice, reinforcing Briumvi’s value proposition. Likewise, positive ENHANCE findings would signal that TG is making Briumvi even more user-friendly (potentially cutting infusion times or visits) – a selling point for patients and neurologists. If the new data are compelling, they could spur increased physician uptake and payer willingness, ultimately translating to higher sales forecasts. Consequently, bullish investors believe TGTX stock could surge on the news, as it would de-risk the growth trajectory and possibly widen Briumvi’s competitive edge.

Competitive Landscape and Implications

It’s important to view the AAN data in context of the MS therapy landscape. Briumvi competes directly against other B-cell targeted MS therapies, chiefly Ocrevus (Roche) and Kesimpta (Novartis). Ocrevus (IV infusion every six months) is currently the market leader, with multi-billion-dollar annual sales (www.biocentury.com). Kesimpta (monthly subcutaneous injections) has also grown rapidly and achieved blockbuster status (www.biocentury.com). Briumvi, which is also IV every 6 months, entered this market as the third player. TG Therapeutics has been carving out share by positioning Briumvi as equally potent but more convenient – it’s the only anti-CD20 antibody for MS that can be infused in a one-hour timeframe (ir.tgtherapeutics.com) (versus Ocrevus’s longer infusion). Also, Briumvi’s launch pricing came in roughly 20% lower than Ocrevus, aiming to attract payers and patients (koalagains.com) (koalagains.com) (this detail is from earlier reports; TG’s strategy was to undercut on price to drive adoption). Early signs are positive: BioCentury reported that Briumvi was already gaining momentum by early 2025 amid the MS market growth (www.biocentury.com). TG Therapeutics cited “increasing adoption” in the U.S. and “expanding global availability” driving 2025 performance (ir.tgtherapeutics.com).

However, competition remains formidable. Roche’s and Novartis’s massive resources and established presences with neurologists mean TG must deliver consistent evidence to continue winning share (koalagains.com) (koalagains.com). Any hint that Briumvi is less effective or less safe than these rivals could hamper its uptake. Conversely, strong data (like superior patient-reported outcomes or easier administration) can be a differentiator. The AAN 2026 data could provide such a differentiator – for instance, if the ENABLE study shows real-world relapse rates or tolerability on par with trials, it validates Briumvi in broader use. Likewise, if the ENHANCE dosing data suggest patients might avoid a second infusion appointment, that convenience could be highlighted in marketing. It’s also worth noting that future competitors are on the horizon: several companies are developing BTK inhibitors for MS, which, if approved, would offer an oral alternative to Briumvi/Ocrevus (though recent BTK trials have hit snags with safety) – so far, the anti-CD20 class remains the gold standard for high-efficacy MS treatment.

Risks

Despite the optimism, TGTX carries significant risks. First and foremost is single-product dependence: Briumvi is essentially TG’s only revenue source (over 96% of 2025 revenue) (ir.tgtherapeutics.com). The company’s future hinges entirely on Briumvi’s commercial success (koalagains.com). Any setback – such as an unexpected safety issue, labeling restriction, or a more effective competitor – could sharply reduce sales and hurt the stock. Investors should recall that all anti-CD20 therapies (including Briumvi) carry a risk of serious infections and PML (progressive multifocal leukoencephalopathy), a rare brain infection. In clinical trials, 3 infection-related deaths occurred in Briumvi-treated patients, and there have been PML cases with drugs like Ocrevus (www.globenewswire.com) (www.globenewswire.com). While these events are rare, they are monitored closely; if any new safety signal emerges for Briumvi, neurologists may become cautious.

Another risk is competition and market share. Briumvi is up against two entrenched giants, and while the MS market is growing, there is a limit to how quickly a newcomer can grab share. Roche and Novartis can leverage extensive sales forces and long-term data to defend their franchises. There is also competition from other classes of MS drugs (like oral S1P modulators and emerging BTK inhibitors) which may limit the addressable share for Briumvi among certain patient segments. Pricing and reimbursement pose a risk as well – TG’s strategy of underpricing Ocrevus helped initial uptake, but insurers could still favor whichever company offers the best rebates. If a price war erupts or if payers impose step-edits (e.g. requiring cheaper therapies first), Briumvi’s growth could slow.

Additionally, operational execution is a risk for a smaller company. Scaling up manufacturing, managing supply for global markets, and conducting post-marketing studies (like ENABLE) all require flawless execution. Any manufacturing hiccup or regulatory compliance issue (e.g. with marketing practices or safety monitoring) could be a red flag. TG Therapeutics has a history of pipeline pivots – for instance, it discontinued development of umbralisib (an oncology drug) due to safety concerns in 2022, after investing heavily in that program. Such past setbacks highlight that R&D can fail and erode shareholder value, although TG’s pivot to MS has thus far been successful. Investors should also consider financial risks: while TG is now profitable, it did burn cash in 2025 and may choose to invest aggressively in new trials or even acquisitions, which could pressure finances. The company’s term loan is covenant-heavy, so a significant earnings miss might trigger debt covenants (though they were in compliance as of YE 2025) (www.sec.gov).

Finally, regulatory and legal risks bear mention. Biotechs often face shareholder lawsuits or regulatory scrutiny. In TG’s case, there have been securities class-action suits in the past related to clinical trial disclosures (www.sec.gov). While there’s nothing current that appears material, these issues can resurface if the stock is volatile or if management’s communications are perceived as overly optimistic.

Red Flags and Observations

Beyond the broad risks, a few red flags warrant attention:

– Product Concentration: As noted, TG’s reliance on one product is a red flag in itself. Briumvi must not only succeed but also stay differentiated through its patent life. Fortunately, TG has shored up its IP – three additional U.S. patents issued in 2024 extend Briumvi’s patent protection to 2042 (www.sec.gov). This gives a long runway if the product remains competitive. But it also means TG is essentially “a one-product company” for the foreseeable future, which amplifies risk. Any sign of waning Briumvi momentum (e.g. flattening prescription trends) would be a major concern.

– Early Pipeline is Thin: The company touts an “allogeneic CAR-T” program (azer-cel) for autoimmune diseases and a subcutaneous Briumvi formulation in Phase 3 (ir.tgtherapeutics.com) (ir.tgtherapeutics.com). These are promising, but they’re mid-to-long-term projects. Azer-cel is in very early trials for progressive MS, a high-risk endeavor, and sub-cutaneous Briumvi, while potentially useful, won’t hit the market for a couple of years if successful (ir.tgtherapeutics.com). In short, there is no diversification of revenue in the near-term – a stark contrast to larger biotechs that have multiple products.

– Management & Insider Activity: CEO Michael S. Weiss has aggressively steered TG through ups and downs. While he successfully led the Briumvi development and pivot to MS, some investors have raised concerns in the past about management’s promotional tone and stock sales (www.stockgumshoe.com). For instance, historically there were instances of insider selling and shareholder lawsuits alleging over-optimism (www.sec.gov). There’s no clear evidence of wrongdoing, but it’s a reminder to watch alignment of management with shareholders. On the positive side, TG did a high-profile awareness campaign with actress Christina Applegate (who has MS) and even a Super Bowl commercial in early 2025 (ir.tgtherapeutics.com), showing management’s commitment to driving Briumvi’s visibility.

– “Value Trap” Concerns: The GuruFocus model flagged TGTX as a possible value trap despite a seemingly low forward P/E (www.gurufocus.com). This likely reflects those “6 warning signs” mentioned (possibly factors like recent cash burn, or reliance on one product). Investors should heed that cheap can sometimes get cheaper in biotech if growth falters. The stock’s volatility is notable – it has traded in a wide range historically (it was under $10 in 2022 before Briumvi’s approval, then spiked above $30 afterwards). Such swings could repeat if news flow disappoints.

In summary, these flags don’t negate the investment case, but underscore the need for caution. TGTX is not a “widows and orphans” stock; it’s a biotech that requires vigilant monitoring of clinical, commercial, and financial developments.

Outlook and Open Questions

Looking ahead, several open questions will determine TGTX’s trajectory:

– Can Briumvi reach blockbuster status? TG’s 2026 revenue guidance is $875–900M (ir.tgtherapeutics.com), implying ~45% growth over 2025 – a strong jump, but still shy of the coveted $1 billion mark. Whether Briumvi can break $1B in annual sales (and continue climbing) will depend on continued uptake in the U.S., rollout in Europe (by partner Neuraxpharm), and possibly expansion into new markets. Early European sales were modest (only ~$22M of 2025 revenue came from outside the U.S.) (ir.tgtherapeutics.com), so international growth is a key opportunity. An open question is how quickly Europe (and other regions) will adopt Briumvi; acceptance in Germany in 2024 was a start (ir.tgtherapeutics.com), but broader EU pricing/reimbursement could take time. Also, can TG secure approvals in other large markets like Canada, Australia, etc.? Hitting the $1B milestone would likely be a bullish catalyst – it proves Briumvi as a true blockbuster.

– Will new data change Briumvi’s usage? The AAN 2026 results and other ongoing studies could expand Briumvi’s profile. For example, if ENABLE (Phase 4) yields compelling outcomes, will guidelines or neurologists start considering Briumvi earlier in the treatment algorithm? Likewise, if ENHANCE (dosing trial) succeeds, could the label be updated to allow a one-infusion start? These improvements might broaden the prescriber base. Also, 5-year extension data (from ULTIMATE I/II) presented earlier already showed sustained efficacy (breakthroughinvestors.com) – an open question is whether long-term data might eventually hint at superiority or unique benefits (for instance, any evidence Briumvi could slow disability in progressive MS better than others). Differentiation is key – so far, Briumvi’s main selling points are infusion time and price; additional clinical differentiation would fortify its market position.

– Pipeline progress? While Briumvi pays the bills, TG’s future could be bolstered by pipeline success. The subcutaneous Briumvi Phase 3 (started in late 2025) aims to give patients a self-injectable option (ir.tgtherapeutics.com). Open question: can TG catch up to Novartis’s Kesimpta convenience by offering Briumvi in a sub-Q form? If yes, that could convert some patients who prefer self-administration, without losing them to Kesimpta. The more ambitious question is azer-cel (CAR-T): Can an off-the-shelf CAR-T cure or durably treat MS? That project is very early, but if it shows even hints of success in progressive MS, it would be game-changing (and likely draw significant investor enthusiasm). However, it’s a high-risk, high-reward bet – akin to developing an entirely new paradigm for autoimmune disease. Progress updates on azer-cel (e.g. when will initial data be reported?) are thus an open question; any positive signal might ignite speculation that TGTX has a “pipeline beyond Briumvi.”

– Will TGTX remain independent? Given Briumvi’s growth, some wonder if TG Therapeutics could become an acquisition target. A larger pharma might covet Briumvi to round out an MS portfolio or simply to buy market share. However, Roche and Novartis – the logical acquirers – already have their own MS cash cows, and an acquisition by them could raise antitrust questions (since it would consolidate the anti-CD20 space). It’s also possible a company outside MS (or wanting entry to neurology) could bid. So far, no concrete rumors have emerged, and TG seems intent on going it alone. But the question lingers: at what point might management consider a buyout offer, if ever? For investors, a takeover would likely come at a premium, but relying on M&A is speculative. It’s safer to invest under the assumption TG will need to execute solo.

– Can TG maintain financial discipline? Now that the company is generating revenue and profits, an open question is how they will balance reinvestment with profitability. TG has guided for a 2026 operating expense (R&D+SG&A) of ~$875M (ir.tgtherapeutics.com), indicating they plan to continue heavy investment in trials and commercialization. Will expenses rise in line with sales, or can TG achieve leverage (growing sales faster than costs)? If Briumvi’s growth slows and costs aren’t trimmed, margins could erode. Conversely, prudent spending could lead to significant earnings leverage given Briumvi’s high gross margins (~84% gross margin in 2025) (ir.tgtherapeutics.com) (ir.tgtherapeutics.com). This ties into another question: when (or if) will TG start returning capital to shareholders? Near-term, no dividends or buybacks are expected (due to growth opportunities and debt restrictions) (www.sec.gov) (www.sec.gov). But if cash flows boom, by late-decade TG might generate surplus cash. Management’s stance on uses of cash – reinvest vs. return – will be an evolving story.

In conclusion, TG Therapeutics’ outlook is optimistic but not without uncertainties. The new Briumvi data at AAN 2026 appears likely to reinforce the drug’s strengths, potentially acting as a positive catalyst for the stock. TGTX offers a classic biotech “high-risk, high-reward” profile (koalagains.com): a rapidly growing product in a large market, counterbalanced by concentrated risk and fierce competition. For investors, the coming months (with AAN data, quarterly sales trends, and pipeline updates) will be critical in determining whether TGTX can continue its upward trajectory or hit some growing pains. If Briumvi’s momentum continues and new data impress, the stock could indeed surge – but it will require flawless execution and a bit of good fortune to fully realize the bullish thesis. As always, a balanced view is warranted: TGTX has tremendous opportunity ahead, but also a lot to prove in the journey from an emerging player to a sustainable biotech success story.

Sources: TG Therapeutics SEC filings and press releases (www.sec.gov) (www.sec.gov) (ir.tgtherapeutics.com) (ir.tgtherapeutics.com); Financial media and analyses (koalagains.com) (www.gurufocus.com) (breakthroughinvestors.com); Industry data on MS market (www.biocentury.com).

For informational purposes only; not investment advice.